Effects of Paullinia cupana extract on lamotrigine pharmacokinetics in rats: A herb-drug interaction on the gastrointestinal tract with potential clinical impact. by Ventura, Sandra et al.
Contents lists available at ScienceDirect
Food and Chemical Toxicology
journal homepage: www.elsevier.com/locate/foodchemtox
Effects of Paullinia cupana extract on lamotrigine pharmacokinetics in rats: A
herb-drug interaction on the gastrointestinal tract with potential clinical
impact
Sandra Venturaa,b, Márcio Rodriguesa,b, Amílcar Falcãoc,d, Gilberto Alvesa,c,∗
a CICS-UBI – Health Sciences Research Centre, University of Beira Interior, Av. Infante D. Henrique, 6200-506 Covilhã, Portugal
bUDI-IPG – Research Unit for Inland Development, Polytechnic Institute of Guarda, 6300-749 Guarda, Portugal
c CNC – Centre for Neuroscience and Cell Biology, University of Coimbra, 3004-517 Coimbra, Portugal
d Laboratory of Pharmacology, Faculty of Pharmacy, University of Coimbra, Pólo das Ciências da Saúde, Azinhaga de Santa Comba, 3000-548 Coimbra, Portugal






A B S T R A C T
Paullinia cupana-containing preparations are being consumed worldwide for weight reduction. As obesity and
epilepsy are common comorbidities and lamotrigine (LTG) is a broad-spectrum antiepileptic drug, it is likely to
find epilepsy patients taking P. cupana and LTG simultaneously. Thus, this work aimed to investigate the po-
tential interaction between P. cupana extract and LTG in rats. In a study, rats were orally co-administered with a
single-dose of P. cupana extract (821mg/kg) and LTG (10mg/kg). In another study, rats were orally pre-treated
for 14 days with P. cupana extract (821mg/kg/day) receiving LTG (10mg/kg, p.o.) on the 15th day. Rats of the
respective control groups received the corresponding volume of the extract vehicle. LTG concentrations were
determined at several post-dose time-points and submitted to a non-compartmental pharmacokinetic analysis.
The co-administration of P. cupana and LTG induced a significant reduction of LTG Cmax and AUC0-24 and
prolonged the mean residence time. However, no significant effects were observed on LTG pharmacokinetics
following a 14-day pre-treatment period with the extract. In this study changes in the body weight of rats and in
some biochemical parameters were also evaluated. Overall, the results revealed a pharmacokinetic-based herb-
drug interaction between P. cupana extract and LTG, mainly after their co-administration.
1. Introduction
Paullinia cupana, also known as Guarana, is a species that belongs to
the Sapindaceae family and it is being consumed worldwide in herbal
supplements and stimulating drinks (Portella et al., 2013). This native
Amazonian plant has been described as having stimulant effects and
other medicinal properties (Schimpl et al., 2013), mainly due to the
presence of caffeine (2–8%) in the seeds of its fruits. Other methyl-
xanthines, like theophylline and theobromine, are also found in small
amounts (< 0.3%) in the seeds, bark, flowers and leaves of P. cupana
(Ashihara et al., 2008; Schimpl et al., 2013). Among several species of
plants that produce caffeine, P. cupana has the higher natural content of
this compound when compared to coffee (Coffea arabica), tea (Camellia
sinensis) and yerba mate (Ilex paraguariensis) (Ashihara and Crozier,
2001; Ashihara et al., 2008). In fact, depending on how the extracts are
prepared, P. cupana extracts may contain caffeine in an amount four
times higher than that found in coffee beans (Moustakas et al., 2015).
Other constituents that can be found in P. cupana seeds are poly-
saccharides, polyphenols (e.g. catechins, epicatechins and tannins), li-
pids, saponins, proteins, choline and pigments (Schimpl et al., 2013).
P. cupana has a well-established medicinal use for symptoms of fa-
tigue and feeling of weakness (EMA, 2013). However, several other
pharmacological effects have been related to P. cupana consumption,
including antiplatelet aggregation, cardioprotective and chemopre-
ventive effects, and also antioxidant, antidepressant, antimicrobial and
anti-obesity properties (Hamerski et al., 2013). Some studies have de-
monstrated that P. cupana-containing products improve lipid metabo-
lism, promote weight loss and increase the basal energy expenditure,
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acting as thermogenics or metabolic stimulants (Glade, 2010; Hamerski
et al., 2013; Portella et al., 2013). Indeed, caffeine increases the ex-
citability of adenosine-sensitive sympathetic nervous system, stimu-
lating fat lipolysis (Glade, 2010).
Overweight and obesity are widely recognized as modifiers of
therapeutic response and prognosis of several chronic health condi-
tions. More specifically, obesity has been commonly reported as a co-
morbid condition of epilepsy, with a high prevalence in children and
adults (Arya et al., 2016; Janousek et al., 2013). Recent studies have
focused on the association between overweight or obesity and epilepsy.
For instance, Ladino et al. (2014) found that 72% of adult patients with
epilepsy present overweight, obesity or even morbid obesity, corre-
sponding respectively to 34%, 25% and 13%. Another study referred to
that 55.2% of patients with epilepsy were overweight or obese
(Janousek et al., 2013). There is also evidence that obesity is more
common in patients with refractory epilepsy and in those treated in
polytherapy regimens (Baxendale et al., 2015; Chukwu et al., 2014;
Janousek et al., 2013). Despite the limited data supporting the role of
obesity in seizure severity, obesity may play a central role in the wor-
sening of this neurological disorder (Hafizi et al., 2017).
Taking into account that the use of herbal dietary supplements has
increased worldwide at an unprecedented rate, and given the growing
prevalence of obesity among patients with epilepsy, it is expected an
increasing consumption of herbal weight loss medicines by this patient
subpopulation over the coming years. Moreover, bearing in mind that
some constituents of plant extracts have been identified as substrates,
inducers and/or inhibitors of transporters and/or enzymes responsible
for antiepileptic drugs (AEDs) biodisposition (Oga et al., 2015; Roe
et al., 2016; Tarirai et al., 2010; Wu et al., 2015), it is important not to
neglect the potential risks associated with the combined use of herbal
medicinal products and AEDs, which may compromise the control of
seizures and even increase the risk of adverse drug reactions.
As lamotrigine (LTG) is an AED extensively used in the clinical
practice, particularly due to its broad spectrum of efficacy in several
types of epileptic disorders (Patsalos, 2013), and considering its narrow
therapeutic range (3–15 μg/mL) (Patsalos et al., 2017) and its phar-
macokinetics variability and propensity to interact with other drugs
(Patsalos, 2013), it is fully justified to investigate the effects of P. cu-
pana extract on the pharmacokinetics of LTG. In fact, up to date, to the
best of our knowledge, no study was previously conducted to evaluate
the potential of interaction between P. cupana and LTG. Therefore, this
work was planned to investigate whether a commercial standardized P.
cupana extract may influence the absorption and biodisposition of LTG
in rats after their oral co-administration and following a 14-day P. cu-
pana pre-treatment period. In addition, the impact of the repeated
treatment with P. cupana extract on the body weight of rats and in some
relevant biochemical parameters was also evaluated.
2. Materials and methods
2.1. Herbal extract, drugs and materials
P. cupana extract from seeds, containing 12% of caffeine, was pur-
chased from Bio Serae Laboratories (Bram, France) and the corre-
sponding certificate of analysis was received and preserved. LTG dis-
persible tablets (Lamictal® 25mg, GSK), chloramphenicol
(Sigma–Aldrich, St Louis, USA), used as internal standard (IS), pento-
barbital (Eutasil®, 200mg/ml, Ceva Saúde Animal), sodium chloride
0.9% solution (Labesfal, Portugal), heparin sodium 5000 I.U./mL (B.
Braun Medical, Portugal), polyurethane cannula (Introcan® Certo IV
indwelling cannula 22G; 0.9× 2.5mm; B. Braun Melsungen AG,
Germany), disposable cholesterol and triglycerides test strips
(Accutrend®, Roche, Germany) and disposable blood glucose test strips
(Freestyle Lite, Abbott®) were commercially acquired.
2.2. Animals
Thirty-four healthy adult male Wistar rats (247 ± 14 g) were ob-
tained from local certified animal facilities (Faculty of Health Sciences
of the University of Beira Interior, Covilhã, Portugal) and housed at
12 h light/dark cycle under controlled environmental conditions
(temperature 20 ± 2 °C; relative humidity 55 ± 5%). The animals
were allowed free access to a standard rodent diet and water ad libitum.
The experimental procedures were approved by the Portuguese
National Authority for Animal Health, Phytosanitation and Food Safety
(DGAV – Direção Geral de Alimentação e Veterinária) and all the an-
imal experiments were conducted in accordance with the European
Directive (2010/63/EU) for animal experiments.
2.3. Preparation of herbal extract and lamotrigine solutions
P. cupana extract solution was daily prepared by dissolving the
powdered extract in distilled water. The dose of P. cupana admini-
strated to each animal was 821mg/kg (p.o.), using an administration
volume of 10mL/kg of rat body weight. The selected dose was defined
taking into account the human dose recommendation from the extract
supplier, which was converted to rat species following a Food and Drug
Administration (FDA) Guidance for Industry, which refers to the con-
version of animal doses to human equivalent doses based on body
surface area (FDA, 2005). Furthermore, a 10-fold potentiating interac-
tion factor was employed to avoid false negative results.
LTG dispersible tablets were dissolved in a proper volume of dis-
tilled water to obtain the LTG solution for rat administration. A LTG
dose of 10mg/kg (p.o.) was administrated taking into consideration an
administration volume of 4mL/kg of rat body weight. LTG dose was
selected according to the previous in-house group experience in rat
studies, and taking also into account that with this dose, saturation
phenomena in the processes of drug absorption and/or elimination are
not probable to occur (Avula and Veesam, 2014; Ventura et al., 2016;
Yamashita et al., 1997).
2.4. Systemic pharmacokinetic studies
Twenty-four rats were randomly distributed in four groups, each
one containing six animals (n=6). These studies were designed to
investigate the effects of P. cupana extract on the bioavailability and
plasmatic kinetics of LTG in two independent experimental assays. In
the first pharmacokinetic study, rats of the experimental group were
concomitantly treated with a single-oral dose of P. cupana extract
(821mg/kg, p.o.) and LTG (10mg/kg, p.o.). In the second study, rats of
the experimental group were orally pre-treated during 14 days with P.
cupana extract (821mg/kg/day, p.o.) followed by a single dose of LTG
(10mg/kg, p.o.) administrated on the 15th day. A 14-day period of
time was considered for the repeated administration of the P. cupana
extract based on available scientific literature (ICH, 2009; Ma and Ma,
2016), in which it is described that repeated administration studies
should be conducted during at least 14 days. Rats of the control groups
received the corresponding volume of the vehicle of the herbal extract
(i.e. water) and were similarly treated with LTG.
In each study, on the night before LTG administration, each animal
was anaesthetized for insertion of an Introcan® Certo IV indwelling
cannula (22G; 0.9×2.5mm) in a lateral tail vein for the subsequent
serial blood sampling. Anesthesia was induced with pentobarbital
(60mg/kg) administered intraperitoneally. The rats fully recovered
from anesthesia and were fasted before LTG administration, but they
were maintained with free access to water. To avoid the food effect on
LTG absorption and biodisposition, the fasting period was maintained
until 4 h after drug administration.
LTG and P. cupana extract (or vehicle, in the control groups) were
orally administrated by gavage during the morning in each study. After
LTG administration, blood sampling was performed at 0.5, 1, 2, 4, 6, 8,
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12, 24, 48, 72 and 96 h post-dose. Blood samples of approximately
0.3 mL were collected into EDTA tubes through the cannula inserted in
the rat tail vein and then centrifuged at 4000 rpm for 10min (4 °C) to
separate the plasma which was stored at −20 ºC until analysis.
2.5. Plasma-to-brain biodistribution study
To further investigate the potential effects of P. cupana on the
plasma-to-brain distribution of LTG an independent study was per-
formed. In this study, ten rats were randomly distributed in two groups,
each one containing five animals (n=5). Each animal received by
gavage a single oral dose of P. cupana extract (821mg/kg, p.o.) or ve-
hicle (in the control group) co-administrated with a single-oral dose of
LTG (10mg/kg, p.o.). Then, in order to measure the LTG concentrations
achieved in plasma and brain at 6 h post-dose, rats were anaesthetized
and sacrificed by decapitation. Blood samples were collected and cen-
trifuged as previously described, and the resulting plasma was stored at
−20 ºC until analysis. Brain tissue was quickly excised after ex-
sanguination, weighed and homogenized in 0.1 M sodium phosphate
buffer at pH 5.5 (4mL per gram of tissue) using an Ultra-Turrax® tissue
homogenizer. The brain tissue homogenates were centrifuged at
13,500 rpm for 10min (4 °C) and the supernatants were collected and
stored at −20 °C until use.
2.6. Liquid chromatography analysis
LTG concentrations in plasma and brain homogenate samples were
determined using a microextraction by packed sorbent (MEPS) proce-
dure combined with a high-performance liquid chromatography–diode
array detection (HPLC-DAD) method previously developed and vali-
dated (Ventura et al., 2016). Briefly, to each aliquot (100 μL) of plasma
or brain homogenate supernatant, spiked with 20 μL of the IS working
solution (250 μg/mL), was added 400 μL of ice-cold acetonitrile (pre-
cipitating agent). The mixture was vortex-mixed for 30 s and cen-
trifuged at 13,500 rpm for 10min to precipitate proteins. The clear
supernatant was collected and evaporated to dryness under a gentle
nitrogen stream at 45 °C. The dry residue was reconstituted with 200 μL
of 0.3% triethylamine-water solution (pH 6.5). Each reconstituted
sample was extracted in three draw-eject cycles through the MEPS
syringe, at a flow rate of 10 μL/s. The sorbent was then washed once
with 200 μL ultra-pure water and, after that, LTG and IS were eluted
with methanol (2×30 μL). This methanolic extract was diluted with
90 μL of ultra-pure water and 20 μL were injected into the chromato-
graphic system. The lower limit of quantification was established at
0.1 μg/mL for LTG in plasma and in brain tissue homogenate.
2.7. Pharmacokinetic analysis
The peak plasma concentration (Cmax) and the time to reach Cmax
(tmax) of LTG were obtained directly from the experimental data. The
remaining pharmacokinetic parameters were estimated from the in-
dividual plasma concentration-time profiles by non-compartmental
pharmacokinetic analysis using WinNonlin version 5.2 (Pharsight Co,
Mountain View, CA, USA). For each animal, the estimated pharmaco-
kinetic parameters included the truncated area under the concentra-
tion-time curve (AUC) from time zero to 24 h (AUC0-24), AUC from time
zero to the last measurable concentration (AUC0-t), which were calcu-
lated by the linear trapezoidal rule; and the AUC from time zero to
infinite (AUC0-∞), which was determined from AUC0-t + (Clast/kel),
where Clast is the quantifiable concentration at the time of the last
measurable drug concentration (tlast) and kel is the apparent elimination
rate constant calculated by log-linear regression of the terminal seg-
ment of the concentration-time profile. The apparent terminal elim-
ination half-life (t1/2el) and the mean residence time (MRT) were also
estimated. The drug concentrations below the lower limit of quantifi-
cation of the assay were taken as zero for all calculations.
2.8. Effects of repeated-dose administration of P. cupana extract on
biochemical parameters
To assess the effects of repeated treatment with P. cupana extract on
biochemical parameters, the blood levels of glucose, total cholesterol
and triglycerides were evaluated in all rats of the experimental (P. cu-
pana) and control (vehicle) groups on the 14th day of the P. cupana
pretreatment study and compared. The blood determination of these
three biochemical parameters was performed using appropriate medical
devices (Accutrend® Plus, Roche, for cholesterol and triglycerides ana-
lysis; and Freestyle Freedom Lite, Abbott®, for glucose analysis) and the
corresponding disposable test strips.
2.9. Effects of repeated-dose administration of P. cupana extract on body
weight
To evaluate the effects of P. cupana extract on rats’ body weight over
the 14 days of treatment, the body weight of the animals of both ex-
perimental (P. cupana) and control (vehicle) groups was determined in
the first and last day (14th) of the P. cupana pretreatment study, and
then compared.
2.10. Statistical analysis
Data are presented as the mean± standard error of the mean
(SEM), except for tmax. As tmax is a categorical variable in the performed
pharmacokinetic studies, which can only take values based on planned
sampling schedule, tmax values were expressed as median and range.
Non-parametric Mann-Whitney test was used to compare the tmax va-
lues from two different groups. The statistical comparisons of the other
pharmacokinetic parameters, body weight and biochemical markers
between two groups were performed using unpaired two-tailed
Student's t-test; in addition, for comparisons of body weight changes
within the same group a paired Student's t-test was employed. A dif-
ference was considered to be statistically significant for a p-value lower
than 0.05 (p < 0.05).
3. Results
3.1. Effects of P. cupana extract on LTG pharmacokinetics after co-
administration
The mean plasma concentration-time profiles (n=6) of LTG ob-
tained in rats after the simultaneous administration of a single-oral dose
of P. cupana extract (821mg/kg) or vehicle and the drug itself (10mg/
kg) are represented in Fig. 1, and the corresponding pharmacokinetic
parameters estimated by applying non-compartmental analysis to each
individual concentration-time profile are summarized in Table 1. From
the observation of the mean plasma pharmacokinetic profiles (Fig. 1), it
is evident the occurrence of important differences in the extent of
systemic exposure to LTG, which was considerably reduced in the
presence of P. cupana extract. A statistically significant decrease in LTG
plasma concentrations was observed in the experimental group, be-
tween 0.5 h and 8 h, when compared to the control group (p < 0.05).
The effect of P. cupana extract was found to be particularly marked on
the LTG Cmax and truncated AUC0-24, which were reduced by 32.6% and
36.6%, respectively (p < 0.05) (Table 1). Nevertheless, only a slight
reduction was observed in the extent of total systemic drug exposure (as
assessed by AUC0-t and AUC0-∞). Despite the statistically significant
differences found in the extent of systemic drug exposure achieved up
to 24 h post-dose, the time to reach the peak plasma concentration of
LTG was similar in both experimental (P. cupana) and control (vehicle)
groups. Specifically, as shown in Table 1, the median values for tmax
were 4 h in both experimental and control groups, with mean values of
8 h and 5.58 h for P. cupana extract group and control group, respec-
tively. Additionally, a statistically significant increase of the MRT value
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of LTG was observed in the experimental group when compared to the
control group (p < 0.05). On the other hand, the mean values esti-
mated for the elimination pharmacokinetic parameters (kel and t1/2el) of
LTG were similar in both groups (P. cupana extract versus vehicle)
(Table 1).
3.2. Effects of repeated-dose pretreatment with P. cupana extract on LTG
pharmacokinetics
The mean plasma pharmacokinetic profiles of LTG following a
single-oral administration of 10mg/kg of the drug (at 15th day) to rats
previously submitted to a 14-day treatment period with P. cupana ex-
tract (821mg/kg/day) or vehicle are depicted in Fig. 2. In addition, the
respective mean (or median) pharmacokinetic parameters are presented
in Table 2. A similar pattern of the plasma concentration-time curves
was observed in both experimental (P. cupana) and control (vehicle)
groups, although slightly higher LTG concentrations were obtained in
the experimental group over most of the study time, presenting statis-
tically significant differences only at 72 h and 96 h post-dose
(p < 0.05). Cmax was slightly higher in the experimental group (16.9%)
compared to the control group. The median LTG tmax was 9 h in the
experimental group and 12 h in the control group, ranging the tmax
values from 4 to 24 h (Table 2). Also worthy of note are the values
estimated for the truncated AUC0-24, which were very similar in both
groups. Regarding the AUC0-t parameter no statistically significant
differences (p > 0.05) were detected, but considering the mean values,
there was a trend towards a higher systemic exposure (36.7%) in the
group of rats treated with P. cupana extract. Otherwise, despite the 96-h
sampling period established for this study, it was not possible to ap-
propriately characterize the terminal elimination phase of the phar-
macokinetic profile of LTG in some rats of the experimental group; thus,
in this case, no reliable conclusions can be drawn by the comparison of
the average values calculated for secondary pharmacokinetic para-
meters, which are highly influenced by the measurements in the
terminal elimination phase of the concentration-time curve (kel, t1/2el,
MRT and AUC0-∞).
3.3. Effects of P. cupana extract on the LTG plasma-to-brain biodistribution
after co-administration
As LTG needs to cross the blood-brain barrier to achieve its bio-
phase, and considering the pharmacokinetic herb-drug interaction
evidenced systemically after the co-administration of P. cupana extract
and LTG, this additional study was designed to evaluate the impact of
such herb-drug interaction on the LTG plasma-to-brain biodistribution,
employing the same dosing regimen (i.e. a single-oral dose of 10mg/kg
of LTG and 821mg/kg of P. cupana extract). For this purpose, LTG
concentrations were measured in plasma and brain tissue of rats sa-
crificed at 6 h post-dose. This time-point was selected because, among
the serial sampling time-points defined in the systemic pharmacokinetic
study described in section 3.1, the 6 h represent a post-dose time-point
that is very close to the median tmax value estimated (6.5 h) considering
together the tmax data (n=12) of both groups (experimental and con-
trol groups). The results obtained are shown in Fig. 3. Analyzing and
comparing the data obtained in this study, it is evident that statistically
significant differences were found between plasma concentrations of
LTG measured in the groups of rats that received P. cupana extract and
vehicle (1.926 ± 0.226 μg/mL versus 3.683 ± 0.239 μg/mL,
p < 0.005). On the other hand, although the mean concentrations of
LTG achieved in brain tissue were lower in the experimental (P. cupana)
Fig. 1. Mean plasma concentration-time profiles of lamo-
trigine (LTG) obtained, over a period of 96 h, from rats co-
administered with a single-dose of Paullinia cupana extract
(821mg/kg, p.o.) or vehicle of the extract (i.e. water) and
LTG (10mg/kg, p.o.) by oral gavage. Symbols represent the
mean values ± standard error of the mean (SEM) of six
determinations per time point (n = 6). *p < 0.05 and
**p < 0.005 compared to control (vehicle).
Table 1
Pharmacokinetic parameters estimated by non-compartmental analysis of the plasma
concentration-time profiles of lamotrigine (LTG) obtained in rats after the co-adminis-
tration with a single-dose of Paullinia cupana extract (821mg/kg, p.o.) or vehicle of the
extract (i.e. water) and LTG (10mg/kg, p.o.) by oral gavage (n=6). Data are presented






Cmax (μg/mL) 2.022 ± 0.222 * 3.00 ± 0.284
tmax (h) 4.0 (2.0–24.0) 4.0 (0.5–12.0)
AUC0-24 (μg.h/mL) 34.028 ± 4.229* 53.642 ± 4.990
AUC0-t (μg.h/mL) 90.383 ± 13.242 106.488 ± 11.692
AUC0-∞ (μg.h/mL) 96.842 ± 13.890 110.660 ± 12.103
kel (1/h) 0.0386 ± 0.0030 0.0415 ± 0.0020
t1/2el (h) 18.5 ± 1.5 16.9 ± 0.8
MRT (h) 38.6 ± 3.1 * 29.1 ± 2.2
AUC, area under the concentration-time curve; AUC0-24, AUC from time zero to 24 h;
AUC0-t, AUC from time zero to the last measurable concentration; AUC0-∞, AUC from time
zero to infinite; Cmax, peak concentration; kel, apparent elimination rate constant; MRT,
mean residence time; t1/2el, apparent terminal elimination half-life; tmax, time to reach
peak concentration. *p < 0.05, significantly different from the control (vehicle) group.
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group (1.389 ± 0.217 μg/g) than in the control (vehicle) group
(1.900 ± 0.256 μg/g), no statistically significant differences were
found at this single point of sampling (p > 0.05).
3.4. Effects of repeated-dose administration of P. cupana extract on
biochemical parameters
The blood levels of glucose, total cholesterol and triglycerides de-
termined in rats treated repeatedly with P. cupana extract (experimental
group) or vehicle (control group), over a period of 14 days, are shown
in Fig. 4. Statistically significant differences were detected between
experimental and control groups for glucose (p < 0.005) and trigly-
cerides (p < 0.05) blood levels. The mean glucose levels measured in
the rats of experimental (P. cupana) group were higher than those found
in rats of control (vehicle) group, which were 74.2 ± 2.8mg/dL and
56.0 ± 2.0mg/dL, respectively. On the contrary, the mean triglyceride
levels determined in the rats treated with P. cupana extract were lower
than those measured in the rats that received the vehicle of the extract
(i.e. water), being 79.2 ± 2.1mg/dL and 94.5 ± 5.5mg/dL, respec-
tively. Regarding the total cholesterol levels, the values obtained were
very similar in both experimental and control groups, with mean con-
centrations of 156.2 ± 1.4mg/dL and 158.7 ± 2.1mg/dL, respec-
tively.
3.5. Effects of repeated-dose administration of P. cupana extract on body
weight
The data regarding body weight of rats treated with P. cupana ex-
tract (821mg/kg/day, p.o) or vehicle during 14 consecutive days are
shown in Fig. 5. The rats of both control and experimental groups had a
Fig. 2. Mean plasma concentration-time profiles of lamo-
trigine (LTG) obtained, over a period of 96 h, from rats
submitted to a 14-day pre-treatment period with Paullinia
cupana extract (821mg/kg/day, p.o.) or vehicle of the ex-
tract (i.e. water), and treated on the 15th day with a single-
dose of LTG (10mg/kg, p.o.) by oral gavage. Symbols re-
present the mean values ± standard error of the mean
(SEM) of six determinations per time point (n=6).
*p < 0.05 compared to control (vehicle).
Table 2
Pharmacokinetic parameters estimated by non-compartmental analysis of the plasma
concentration-time profiles of lamotrigine (LTG) obtained in rats submitted to a 14-day
pre-treatment period with Paullinia cupana extract (821mg/kg, p.o.) or vehicle of the
extract (i.e. water), and treated on the 15th day with a single-dose of LTG (10mg/kg,
p.o.) by oral gavage (n= 6, unless otherwise noted). Data are presented as mean va-






Cmax (μg/mL) 3.165 ± 0.358 2.706 ± 0.237
tmax (h) 9.0 (4.0–24.0) 12.0 (4.0–24.0)
AUC0-24 (μg.h/mL) 55.398 ± 6.973 49.195 ± 5.578
AUC0-t (μg.h/mL) 150.108 ± 11.737 109.770 ± 15.950
AUC0-∞ (μg.h/mL) 157.212 ± 26.779a 118.699 ± 18.679
kel (1/h) 0.0229 ± 0.0041a 0.0419 ± 0.0050
t1/2el (h) 31.2 ± 5.6a 18.1 ± 2.5
MRT (h) 45.7 ± 10.3a 32.8 ± 5.2
AUC, area under the concentration-time curve; AUC0-24, AUC from time zero to 24 h;
AUC0-t, AUC from time zero to the last measurable concentration; AUC0-∞, AUC from time
zero to infinite; Cmax, peak concentration; kel, apparent elimination rate constant; MRT,
mean residence time; t1/2el, apparent terminal elimination half-life; tmax, time to reach
peak concentration. a n= 2.
Fig. 3. Mean plasma and brain tissue concentrations of lamotrigine (LTG), obtained at 6 h
post-dose, from rats co-administrated with a single-dose of Paullinia cupana extract
(821mg/kg, p.o.) or vehicle (i.e. water) and LTG (10mg/kg, p.o.) by oral gavage. Data
are presented as the mean values ± standard error of the mean (SEM) of five determi-
nations (n=5). **p < 0.005 compared to control (vehicle).
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similar body weight at the beginning of the study (day 1), with mean
values of 250.7 ± 6.0 g and 243.3 ± 5.4 g, respectively. From the
results obtained, a statistically significant increase in the body weight of
rats was observed between day 1 and day 14 in both experimental (P.
cupana) and control (vehicle) groups (p < 0.005). When comparing the
body weight gains of the rats during the period of the study, a trend
towards a lower weight increase was observed in the rats that received
P. cupana extract, however, such difference was not found to be sta-
tistically significant (p=0.06).
4. Discussion
The goal of AED therapy is to control seizures and improve the
patient's quality of life. Drug-related problems, including those re-
sulting from interactions between herbal substances and AEDs can in-
fluence the efficacy, safety and adherence to AED therapy. Also of
concern is the fact that many patients believe in the safety of herbal
medicines and therefore do not report its use to the physician. In a study
involving 92 patients with epilepsy, it was found that 24% were using
complementary and alternative therapies, of which 41% were using
herbs and supplements and, in most cases, it was not of the doctor's
knowledge (Peebles et al., 2000). In a more recent study conducted by
Eyal et al. (2014), in adult patients with epilepsy, the results showed
that 48% of them took dietary supplements simultaneously with AEDs
and patient awareness for potential drug interactions involving AEDs
was very limited.
The pharmacokinetic studies herein reported were designed to as-
sess the potential of interaction between P. cupana extract and LTG in
vivo in Wistar rats. Considering that no interaction has been previously
reported among these components, our starting point for a preliminary
preclinical risk assessment was to evaluate the effects of P. cupana ex-
tract on the LTG bioavailability after their simultaneous administration,
aiming at investigating a possible interference of P. cupana extract on
the gastrointestinal absorption of LTG. In these experimental condi-
tions, the obtained pharmacokinetic results clearly evidenced a de-
crease in absorption rate of LTG from the gastrointestinal tract of rats
(as denoted by Cmax and AUC0-24), even though no important differ-
ences were detected in the extent of total systemic drug exposure (as
assessed by AUC0-t and AUC0-∞). These findings support that P. cupana
extract, or some of its constituents, interact in some way with LTG in
the gastrointestinal tract of rats, delaying the drug absorption. These
data converge with results previously reported by our research group in
a similar study involving P. cupana extract and amiodarone, in which a
significant reduction in the peak plasma concentration (73.2%) and in
the extent of systemic exposure (57.8%) to amiodarone were found
(Rodrigues et al., 2012). The simultaneous co-administration of a Fucus
vesiculosus extract and amiodarone also resulted in a significant de-
crease (55.4%) of the peak plasma concentration and in a reduction of
approximately 30% in the extent of systemic exposure to amiodarone
(Rodrigues et al., 2013). Moreover, similar results were found in vivo
after oral pretreatment of rats with green tea extract (175mg/kg/day)
for 4 days followed by a single-dose administration of clozapine 20mg/
kg, which resulted in a significant decrease of Cmax and AUC0-∞. The
authors suggested that green tea extract delayed the gastric emptying of
clozapine, reducing the rate and amount of clozapine absorbed (Jang
Fig. 4. Effects of Paullinia cupana extract on biochemical parameters (blood glucose, total
cholesterol and triglycerides) after a 14-day treatment period with Paullinia cupana ex-
tract (821mg/kg/day, p.o.) or vehicle (water) by oral gavage. Data are presented as the
mean values ± standard error of the mean (SEM) of six determinations (n=6).
*p < 0.05 and **p < 0.005 compared to control (vehicle).
Fig. 5. Effects of Paullinia cupana extract on the body weight of rats after a 14-day treatment period with Paullinia cupana extract (821mg/kg/day, p.o.) or vehicle (i.e. water) by oral
gavage. Data are presented as the mean values ± standard error of the mean (SEM) of six determinations (n=6). **p < 0.005, day 1 versus day 14.
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et al., 2005).
Moreover, having in mind the central role that induction of enzymes
and transporters plays on drug-drug and herb-drug interactions, and
knowing that the induction mechanisms are time-dependent, a second
study was delineated to evaluate the effects of the repeated adminis-
tration of P. cupana extract on the pharmacokinetics of LTG. The P.
cupana extract pretreatment for 14 days resulted in a slightly higher
systemic exposure to LTG, however, no important differences were
found in comparison with the control group. These results suggest that
P. cupana extract can interact with LTG disposition, but the similarity
observed in the extent of systemic drug exposure in the rats of both
experimental and control groups excludes the impact of P. cupana-in-
duced metabolism on the bioavailability of LTG. Therefore, by com-
bining the results of the two pharmacokinetic studies, it can be inferred
that the herb-drug interaction between P. cupana extract and LTG found
in the co-administration study occurred mainly at the absorption level,
being unlikely the involvement of metabolism-based mechanisms.
Indeed, as LTG has an oral bioavailability of approximately 100% and
its absorption is not affected by food (Garnett, 1997), and taking also
into account the available evidence that LTG permeates through bio-
logical mucosa mainly via the non-storable transcellular passive diffu-
sion (Mashru et al., 2005), there is a negligible probability of this re-
ported herb-drug interaction being the result of competition
mechanisms by the same carrier. Thus, considering all the results pre-
sented herein, it is plausible to hypothesize that a physical-chemical
interaction occurred between P. cupana extract, or its constituents, and
LTG in the gastrointestinal tract of rats, which may explain the decrease
in the rate of systemic exposure to LTG after its simultaneous co-ad-
ministration with P. cupana extract. Thus, we presume that the effect of
P. cupana extract could be related to the adsorption of lamotrigine in an
identical manner to the effect caused by charcoal on lamotrigine
(Keränen et al., 2011). Nevertheless, further studies are needed to
better understand the mechanism associated with this herb-drug in-
teraction (P. cupana extract/LTG), which is herein reported for the first
time. Although there are pharmacokinetic differences between species,
the effective plasma levels of AEDs are usually quite similar among
rodents and humans (Castel-Branco et al., 2005; Loscher, 2011); hence,
the clinical relevance of this interaction must be further investigated in
order to understand the therapeutic impact of a lower systemic in-
corporation rate of LTG.
The repeated administration of P. cupana extract for 14 days had
effects on glucose and triglyceride levels, increasing the glycaemia and
reducing the blood levels of triglycerides. Another study identified si-
milar results in rats treated with P. cupana extract, showing an increase
in the glycaemia and a decrease in blood triglyceride levels in the ex-
perimental groups (Antonelli-Ushirobira et al., 2010). The reduction in
blood triglyceride levels after P. cupana intake was also observed in
human studies (Krewer et al., 2011; Portella et al., 2013; Suleiman
et al., 2016). Indeed, caffeine, a methylxanthine abundantly present in
P. cupana extract, has already been related to inhibitory effects on
pancreatic lipase, a key enzyme in the dietary absorption of tria-
cylglycerols (Yun, 2010). Portella et al. (2013) also demonstrated that
P. cupana extract has peroxyl radical scavenger activity and inhibits
lipid peroxidation, which may explain the impact of the extract on the
lipid metabolism. Although no statistically significant difference was
observed in cholesterol levels, methylxanthines have been related to the
control of the transcription of genes for 3-hydroxy-3-methylglutaryl
coenzyme A reductase and low density lipoprotein receptor (Ruchel
et al., 2017). Likewise, the 14-day treatment period with P. cupana
extract did not have a strong effect on the body weight of rats; however,
according to the available data, there appears to be a tendency for a
slower weight gain in the rats of the experimental (P. cupana) group.
Antonelli-Ushirobira et al. (2010) also found no statistically significant
differences in rats’ body weight after 14 days of administration of P.
cupana extract; nevertheless, when the animals were treated for a
longer period of time (90 days) a slower increase in the body weight
gain was observed. These effects of P. cupana extract intake on the body
weight of rats and in the measured biochemical parameters reinforce
the potential benefits of this extract in weight management and in lipid
metabolism.
5. Conclusion
This work is the first report documenting the occurrence of a herb-
drug interaction between P. cupana and LTG after their simultaneous
co-administration, which led to a significant reduction in the rate and
extent of systemic exposure to LTG. On the other hand, the repeat
pretreatment with P. cupana did not have a significant impact on LTG
concentrations when the drug was administered 24 h after the last ad-
ministration of the extract. Thus, bearing in mind the effects of P. cu-
pana extract on the systemic absorption of LTG, it is prudent to advise
patients on therapy with LTG to avoid the simultaneous ingestion of P.
cupana-containing products, thus minimizing the risks of occurrence of
interaction. However, if the treatment with P. cupana-containing pro-
ducts and LTG is required at the same time in a patient, then they
should be administered separately on the day (one in the morning and
the other in the evening).
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